Moderna: Initial booster data shows good results on omicron

  • A woman receives Moderna COVID-19 vaccine as riders train at the National Velodrome in Saint-Quentin-en-Yvelines, west of Paris, France, Friday, Dec. 17, 2021. The government is holding a special virus security meeting Friday to address growing pressure on hospitals in France from rising infections.

    A woman receives Moderna COVID-19 vaccine as riders train at the National Velodrome in Saint-Quentin-en-Yvelines, west of Paris, France, Friday, Dec. 17, 2021. The government is holding a special virus security meeting Friday to address growing pressure on hospitals in France from rising infections. Associated Press

  • A man receives Moderna COVID-19 vaccine at the National Velodrome in Saint-Quentin-en-Yvelines, west of Paris, France, Friday, Dec. 17, 2021. The government is holding a special virus security meeting Friday to address growing pressure on hospitals in France from rising infections.

    A man receives Moderna COVID-19 vaccine at the National Velodrome in Saint-Quentin-en-Yvelines, west of Paris, France, Friday, Dec. 17, 2021. The government is holding a special virus security meeting Friday to address growing pressure on hospitals in France from rising infections. Associated Press

 
 
Updated 12/20/2021 12:16 PM

Moderna said Monday that a booster dose of its COVID-19 vaccine should offer protection against the rapidly spreading omicron variant.

Moderna said lab tests showed the half-dose booster shot increased by 37 times the level of so-called neutralizing antibodies able to fight omicron.

 

And a full-dose booster was even stronger, triggering an 83-fold jump in antibody levels, although with an increase in the usual side effects, the company said. While half-dose shots are being used for most Moderna boosters, a full-dose third shot has been recommended for people with weakened immune systems.

Moderna announced the preliminary laboratory data in a press release and it hasn't yet undergone scientific review. But testing by the U.S. National Institutes of Health, announced last week by Dr. Anthony Fauci, found a similar jump.

Pfizer's testing likewise found its COVID-19 vaccine triggered a similarly big jump in omicron-fighting antibodies. The vaccines made by Pfizer and by Moderna, both made with mRNA technology, are used by many countries around the world to fight the coronavirus.

Together, the available evidence backs health authorities'' increasing pleas for people to get their boosters as soon as they're eligible.

Antibody levels predict how well a vaccine may prevent infection with the coronavirus but they are just one layer of the immune system's defenses. Other research suggests the vaccine still should induce good protection against severe disease if people do experience a breakthrough infection.

by signing up you agree to our terms of service
                                                                                                                                                                                                                       
 

Both Moderna and Pfizer are developing shots to better match the omicron variant in case they're needed.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Department of Science Education. The AP is solely responsible for all content.

0 Comments
                                                                                                                                                                                                                       
 
Article Comments
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.